Canada's QSV Biologics to make Helix BioPharma's lung cancer drug for trials
QSV Biologics (QSV), a privately held contract manufacturer based in Alberta, Canada, is to develop a cGMP manufacturing process for Helix BioPharma Corp's L-DOS47, to be used in the treatment of lung cancer.
QSV Biologics (QSV), a privately held contract manufacturer based in Alberta, Canada, is to develop a cGMP manufacturing process for Helix BioPharma Corp's L-DOS47, to be used in the treatment of lung cancer.
Also located in Canada, Helix Biopharma says the deal will accelerate the cGMP production of L-DOS47 for upcoming preclinical and human clinical studies.
L-DOS47 combines Helix Biopharma's proprietary DOS47 new drug candidate with a highly specific antibody, to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung, the most common form of cancer in the world today.
L-DOS47 is thought to function by leveraging a natural process in the body called the urea cycle, to produce an anti-cancer effect.